Kiniksa Pharmaceuticals International, Plc (NASDAQ: KNSA)
Kiniksa Pharmaceuticals International, Plc Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Kiniksa Pharmaceuticals International, Plc Company Info
Kiniksa Pharmaceuticals Ltd. is a biopharmaceutical company, which engages in discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Its products include Rilonacept, Mavrilimumab, Vixarelimab, and KPL-404. The company was founded by Sanj K. Patel, Stephen Frank Mahoney, Krisha S. Mahoney, Thomas W. Beetham, Christopher Heberlig, Carsten Boess, Rasmus Holm-Jorgensen, Gregory Alex Grabowksi, Aaron Isadore Young, Eben P. Tessari, Jennifer Lynne Mason and Mickenzie Elizabeth Gallagher in July 2015 and is headquartered in Lexington, MA.
News & Analysis
Kiniksa Pharm's Revenue Surges 67% in Q3
Sales of its only commercialized treatment, Arcalyst, exceeded analysts' expectations.
Why Shares of Kiniksa Pharmaceuticals Jumped Tuesday
The company reported a big jump in revenue and updated guidance.
3 Top Biotech Stocks to Buy in February
These three clinical-stage biotechs could all double in value before year's end.
Why Canopy Growth, Kiniksa Pharmaceuticals, and Paycom Software Jumped Today
A much-needed vote of confidence lifted an entire industry.
Here's Why Kiniksa Pharmaceuticals Rose as Much as 36.7% Today
The company's lead drug candidate earned Breakthrough Therapy designation from American regulators.
Are These 3 Beaten-Down Biotech Stocks Bargains Now?
Some investors think the market's been too hard on these drugmakers.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.